Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Transmembrane protein 30C, pseudogene (TMEM30CP) is classified as a pseudogene in Homo sapiens. Unlike its protein-coding paralogs (such as TMEM30A and TMEM30B), TMEM30CP does not encode a functional protein. Pseudogenes are genomic DNA sequences similar to normal genes but are typically nonfunctional; they often result from gene duplication or retrotransposition and accumulate mutations rendering them transcriptionally or translationally inactive[4][5][6]. Although the name and some aliases may be shared with functional P4-ATPase beta subunit family members, there is no evidence that TMEM30CP product is biologically active, acts as a receptor, or serves as a therapeutic target[4][5][6]. There are no described roles in disease, no approved or experimental drugs, and no established use as a biomarker. Any mention of biological or therapeutic function refers to other family members, not TMEM30CP.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Cell cycle control protein 50C, pseudogene (TMEM30CP).